Cargando…

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements

SIMPLE SUMMARY: Breast cancer remains the fourth-leading cause of death worldwide, and therapeutic improvement is warranted. The phosphatidylinositol 3-kinase (PI3K) pathway is one of the major pathways in oncogenesis, and PI3K alterations are common in all breast cancer subtypes. Despite modest cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertucci, Alexandre, Bertucci, François, Gonçalves, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001361/ https://www.ncbi.nlm.nih.gov/pubmed/36900211 http://dx.doi.org/10.3390/cancers15051416

Ejemplares similares

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
por: Gonçalves, Anthony, et al.
Publicado: (2020)

Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Wu, Peng, et al.
Publicado: (2012)

MON-LB128 Phosphoinositide 3-Kinase (PI3K) Inhibitor Induced Hyperglycemia With Alpelisib
por: Barsukova, Yuliya, et al.
Publicado: (2020)

Signaling via Class IA Phosphoinositide 3-Kinases (PI3K) in Human, Breast-Derived Cell Lines
por: Juvin, Veronique, et al.
Publicado: (2013)

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
por: Jung, Kyungsuk, et al.
Publicado: (2018)

Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia
por: Shey, Susan, et al.
Publicado: (2021)

Beyond PI3Ks: targeting phosphoinositide kinases in disease
por: Burke, John E., et al.
Publicado: (2022)

Discovery of Novel Dual Extracellular Regulated Protein Kinases (ERK) and Phosphoinositide 3-Kinase (PI3K) Inhibitors as a Promising Strategy for Cancer Therapy
por: Zhang, Lingzhi, et al.
Publicado: (2020)

Discovery of hydrazide-based pyridazino[4,5-b]indole scaffold as a new phosphoinositide 3-kinase (PI3K) inhibitor for breast cancer therapy
por: Sarhan, Ahmed A. M., et al.
Publicado: (2020)

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Shuttleworth, S.J, et al.
Publicado: (2011)

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
por: Faia, Kerrie, et al.
Publicado: (2018)

Discovery of a novel phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor against hematologic malignancies and theoretical studies on its PI3Kγ-specific binding mechanisms
por: Zhu, Jingyu, et al.
Publicado: (2019)

Genetic enhancement of behavioral itch responses in mice lacking phosphoinositide 3-kinase-γ (PI3Kγ)
por: Lee, Bolam, et al.
Publicado: (2011)

The Phosphoinositide 3-Kinase Isoform PI3Kβ Regulates Osteoclast-Mediated Bone Resorption in Humans and Mice
por: Győri, Dávid, et al.
Publicado: (2014)

Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases
por: Rodgers, Samuel J., et al.
Publicado: (2017)

Direct Association of Heat Shock Protein 20 (HSPB6) with Phosphoinositide 3-kinase (PI3K) in Human Hepatocellular Carcinoma: Regulation of the PI3K Activity
por: Matsushima-Nishiwaki, Rie, et al.
Publicado: (2013)

The anticancer activities of Vernonia amygdalina Delile. Leaves on 4T1 breast cancer cells through phosphoinositide 3-kinase (PI3K) pathway
por: Hasibuan, Poppy Anjelisa Zaitun, et al.
Publicado: (2020)

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
por: Keegan, Niamh M., et al.
Publicado: (2021)

Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects
por: Jhamnani, Rekha D., et al.
Publicado: (2018)

Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors
por: Xin, Minhang, et al.
Publicado: (2018)

QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using MLR and ANN methods
por: Sadeghi, Fereydoun, et al.
Publicado: (2022)

Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
por: Aydin, Ebru, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition
por: Weintraub, Michael A, et al.
Publicado: (2023)

Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse
por: Hu, Xiwen, et al.
Publicado: (2016)

Regulation of heart rate and the pacemaker current by phosphoinositide 3-kinase signaling
por: Lin, Richard Z., et al.
Publicado: (2019)

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth
por: Mishra, Rosalin, et al.
Publicado: (2021)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Opportunistic Infections (OIs) in Patients with Hematologic Malignancies (HM) Treated with Bruton’s Tyrosine Kinase (BTK) and Phosphoinositide 3 Kinase (PI3K) Inhibitors: An 8-Year Retrospective Cohort Study
por: Issa, Nicolas, et al.
Publicado: (2017)

Berberine Induced Apoptosis of Human Osteosarcoma Cells by Inhibiting Phosphoinositide 3 Kinase/Protein Kinase B (PI3K/Akt) Signal Pathway Activation
por: CHEN, Zhi-Ze
Publicado: (2016)

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
por: Huw, L-Y, et al.
Publicado: (2013)

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors
por: Schwarzenbacher, Daniela, et al.
Publicado: (2019)

Functional Redundancy of Class I Phosphoinositide 3-Kinase (PI3K) Isoforms in Signaling Growth Factor-Mediated Human Neutrophil Survival
por: Juss, Jatinder K., et al.
Publicado: (2012)

Structure of the phosphoinositide 3-kinase (PI3K) p110γ-p101 complex reveals molecular mechanism of GPCR activation
por: Rathinaswamy, Manoj K., et al.
Publicado: (2021)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

The Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P(3)) Binder Rasa3 Regulates Phosphoinositide 3-kinase (PI3K)-dependent Integrin α(IIb)β(3) Outside-in Signaling
por: Battram, Anthony M., et al.
Publicado: (2017)

Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS)
por: Burke, John E., et al.
Publicado: (2013)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling
por: Maffucci, Tania, et al.
Publicado: (2020)

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
por: Park, Jeong Su, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lfnj904bfocldkhail7curffaq